Skip to main content
Monday, August 17, 2026
BTC $64,183 ▲ 1.50%
GOKHSHTEIN.
Live WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
More SectionsDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
Subscribe
LIVE
BTC$64,183up+1.50%ETH$1,909up+1.20%SOL$75.94up+0.60%XRP$1.00up+0.10%LINK$9.51up+1.90%ADA$0.174down−1.50%S&P 5007,763down−0.29%Nasdaq26,675down−0.20%Dow53,545down−0.35%RUT3,061down−0.23%TNX4.71%up+0.34%TYX5.29%up+0.57%FVX4.37%up+0.11%IRX3.70%up+0.00%VIX15.23up+6.88%GOLD$4,479.60up+0.95%SILVER$66.49up+2.11%OIL$83.41up+1.23%DXY99.50down−0.16%NVDA$226.09up+0.41%AAPL$304.31down−0.53%TSLA$339.68down−0.76%META$567.30down−3.82%MSFT$479.59down−3.19%AMZN$258.78down−1.47%GOOGL$343.90down−0.58%Fear & Greed31 — FearBTC$64,183up+1.50%ETH$1,909up+1.20%SOL$75.94up+0.60%XRP$1.00up+0.10%LINK$9.51up+1.90%ADA$0.174down−1.50%S&P 5007,763down−0.29%Nasdaq26,675down−0.20%Dow53,545down−0.35%RUT3,061down−0.23%TNX4.71%up+0.34%TYX5.29%up+0.57%FVX4.37%up+0.11%IRX3.70%up+0.00%VIX15.23up+6.88%GOLD$4,479.60up+0.95%SILVER$66.49up+2.11%OIL$83.41up+1.23%DXY99.50down−0.16%NVDA$226.09up+0.41%AAPL$304.31down−0.53%TSLA$339.68down−0.76%META$567.30down−3.82%MSFT$479.59down−3.19%AMZN$258.78down−1.47%GOOGL$343.90down−0.58%Fear & Greed31 — Fear
GOKHSHTEIN.
Media · Est. 2019
The front page of everything. Breaking news and sharp analysis across politics, markets, crypto, technology, and sports — with live market data built in.
Markets
Market OverviewDigital AssetsU.S. EquitiesMacro & RatesResearch
Editorial
Politics & PolicyTechnologySports BusinessResearch
Terminal
GMarketsGo PRO
Company
AboutContactEditorial StandardsCorrectionsAdvertiseSubscribe
Legal
Privacy PolicyTerms of ServiceDisclosures
© 2026 Gokhshtein Media. All rights reserved.
PrivacyTermsDisclosures
Tag

tango therapeutics

1 article

Jefferies Initiates Freenome With Buy, Sees 47% Upside in Cancer Screening
U.S. Equities2h ago
Jefferies Initiates Freenome With Buy, Sees 47% Upside in Cancer Screening
Jefferies set a $17 price target on Freenome (FRNM), trading at $11.56, citing the company's cancer screening potential as the core catalyst